{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:15:53Z","timestamp":1791422153480,"version":"4.3.3"},"reference-count":25,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"208","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Transl. Med."],"published-print":{"date-parts":[[2013,10,23]]},"abstract":"<jats:p>In patients with advanced chemotherapy-refractory mesothelioma, treatment with the anti-mesothelin immunotoxin SS1P and immunosuppression with pentostatin and cyclophosphamide resulted in marked and durable tumor regressions.<\/jats:p>","DOI":"10.1126\/scitranslmed.3006941","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T14:25:43Z","timestamp":1382538343000},"source":"Crossref","is-referenced-by-count":198,"title":["Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression"],"prefix":"10.1126","volume":"5","author":[{"given":"Raffit","family":"Hassan","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Miller","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[{"name":"Medical Oncology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ling","sequence":"additional","affiliation":[{"name":"Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kreitman","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku M.","family":"Miettinen","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Section, CCR, NCI, NIH, Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050152"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8523"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9640"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.136"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0801"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.2.669"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0869"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0062"},{"key":"e_1_3_2_11_2","first-page":"345","article-title":"Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: Results of a phase II trial.","volume":"9","author":"Oratz R.","year":"1990","unstructured":"Oratz R., Speyer J. L., Wernz J. C., Hochster H., Meyers M., Mischak R., Spitler L. E., Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: Results of a phase II trial. J. Biol. Response Mod. 9, 345\u2013354 (1990).","journal-title":"J. Biol. Response Mod."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199304000-00007"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1160-3"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0493"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2245"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31823f45c1"},{"key":"e_1_3_2_17_2","first-page":"459","article-title":"Pentostatin: Future directions.","volume":"44","author":"Klohs W. D.","year":"1992","unstructured":"Klohs W. D., Kraker A. J., Pentostatin: Future directions. Pharmacol. Rev. 44, 459\u2013477 (1992).","journal-title":"Pharmacol. Rev."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.1007"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1390-6"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_3_2_23_2","unstructured":"Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (National Cancer Institute Bethesda MD 2009); http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh059"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"}],"container-title":["Science Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/scitranslmed.3006941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T13:31:20Z","timestamp":1705411880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.3006941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,23]]},"references-count":25,"journal-issue":{"issue":"208","published-print":{"date-parts":[[2013,10,23]]}},"alternative-id":["10.1126\/scitranslmed.3006941"],"URL":"https:\/\/doi.org\/10.1126\/scitranslmed.3006941","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718153906.793501130","asserted-by":"object"}]},"ISSN":["1946-6234","1946-6242"],"issn-type":[{"value":"1946-6234","type":"print"},{"value":"1946-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,23]]}}}